Palisade Bio Inc. is a late-stage biopharma company advancing therapies which help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio Inc., formerly known as Seneca Biopharma Inc., is based in CARLSBAD, Calif.
| Revenue (Most Recent Fiscal Year) | $0.25M |
| Net Income (Most Recent Fiscal Year) | $-16.78M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.08 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -6388.20% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -33.47% |
| Return on Assets (Trailing 12 Months) | -31.79% |
| Current Ratio (Most Recent Fiscal Quarter) | 24.26 |
| Quick Ratio (Most Recent Fiscal Quarter) | 24.26 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.70 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.05 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.30 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 174.27M |
| Free Float | 174.15M |
| Market Capitalization | $376.42M |
| Average Volume (Last 20 Days) | 1.88M |
| Beta (Past 60 Months) | 1.52 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.07% |
| Percentage Held By Institutions (Latest 13F Reports) | 11.79% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |